HGH Fragment 176-191 is the last sixteen amino acids of a 191-residue hormone, sold on the premise that fat-related activity can be separated from growth-related activity. That premise is real pharmacology traced to work in the late 1970s and 1980s, and the cost of acting on it falls on the buyer: animal data are the strongest evidence that exists, and the confirmatory human trial of the fragment's commercial analogue did not separate from placebo.
| Property | HGH Fragment 176-191 | Recombinant somatotropin |
|---|---|---|
| Size | 16 residues, roughly 1.8 kDa | 191 residues, roughly 22 kDa |
| Receptor dimerization | Not reproduced | Site 1 and site 2 binding, JAK2/STAT5 |
| IGF-1 response | Absent in animal work | Raised, dose dependent |
| Approval status | None, any indication, any country | Approved prescription biologic |
HGH Fragment 176-191 is the carboxyl-terminal sixteen residues of the 191-amino-acid somatotropin chain, holds no drug approval in any country, and reached human efficacy testing only through its analogue AOD-9604, which failed its confirmatory obesity trial.
The sequence printed on a vial label identifies which molecule is inside it. Native 176-191 begins with phenylalanine, while the tyrosine-led sequence that appears throughout supplier material is AOD-9604, a different compound built on residues 177 to 191 with a tyrosine added at the amino terminus. Supplier naming treats the two as synonyms, and that is where most of the literature confusion starts.
The native 176-191 segment reads FLRIVQCRSVEGSCGF and sits after the fourth alpha helix of somatotropin's four-helix bundle, while the widely circulated YLRIVQCRSVEGSCGF sequence is the analogue AOD-9604 rather than the native fragment.
Almost everything a prescription buys with growth hormone therapy is gone when only the C-terminal tail is kept. Intact somatotropin brings two receptor copies together, activating JAK2 and phosphorylating STAT5, and that single cascade produces hepatic IGF-1 output, growth-plate activity, nitrogen retention, and the insulin antagonism that makes supraphysiologic dosing diabetogenic. The fragment does not engage that receptor with meaningful affinity, which the original investigators treated as the design goal rather than a defect.
| Function | Intact somatotropin | 176-191 fragment |
|---|---|---|
| Receptor signaling | JAK2/STAT5 via dimerization | No meaningful affinity |
| Hepatic IGF-1 | Raised | Unchanged in animal work |
| Longitudinal bone growth | Tibial and length gain | None recorded |
| Insulin antagonism | Diabetogenic at high dose | Glucose tolerance unimpaired |
| Prolactin receptor affinity | Appreciable | No structural basis |
Because the fragment does not dimerize the growth hormone receptor, marketing claims of muscle gain, anti-aging, recovery, or height borrowed from somatotropin are mechanistically implausible rather than simply unproven.
Consumer material describes the fat-tissue effect as if a pathway had been mapped. The published record instead holds downstream markers, a candidate pathway that failed its own test, and no identified molecular target.
The beta-3 adrenergic receptor was the leading proposed mediator, and the knockout experiments led the investigators to conclude that the lipolytic action is not directly mediated through it, which leaves the fragment with a descriptive mechanism and no defined molecular target.
The rodent record is real, and it is narrow. Most of the cited work used genetically obese mouse strains, a leptin-pathway disease model rather than a stand-in for common human obesity with its behavioral, hormonal, and environmental drivers. Base rates weigh on the reading of it, since most compounds that shrink fat mass in rodents fail to show clinically useful effects in adequately powered human trials.
The preclinical evidence rests mainly on genetically obese mouse strains dosed over multiple weeks, with rodent exposures that were never the source of the dosing conventions circulating on the consumer market.
Human testing was carried out on AOD-9604, not on the unmodified 176-191 peptide, and consumer material routinely erases that distinction. The gap between untested and tested-and-failed carries more weight than anything else in this record, because this molecule entered a trial designed to detect a clinically useful effect and did not produce one.
The only controlled human efficacy data belong to AOD-9604, where a twelve-week phase 2 study reported about 2.6 kilograms lost against 0.8 kilograms on placebo before a larger confirmatory trial failed to separate from placebo, and no controlled human efficacy trial of the injected native 176-191 sequence has been published.
Pharmacokinetics separate these two molecules as sharply as pharmacology does. A sixteen-residue chain is small enough for renal filtration and exposed on all sides to serum and tissue peptidases, so peptides in this size class carry circulating half-lives measured in minutes unless the sequence is deliberately engineered for stability. Reconstituted material runs a second clock, since potency falls with time, temperature, freeze-thaw cycling, and light, and no end user can measure what remains.
| Property | Recombinant somatotropin | Unmodified 16-residue fragment |
|---|---|---|
| Subcutaneous half-life | Roughly 2 to 4 hours | Minutes for this size class |
| Long-acting formulations | Pegylation, protein fusion, prodrug | None available |
| Clearance exposure | Formulated biologic | Renal filtration plus peptidase attack |
| Oral route | Not used clinically | Acid and protease degradation, poor gut permeability |
Recombinant somatotropin given subcutaneously carries an absorption-limited half-life of roughly two to four hours, with long-acting versions extending that to weekly dosing, while an unmodified sixteen-residue peptide has no such protection and clears on a scale of minutes.
The regulatory gap between the two molecules is not a technicality. One is an approved prescription biologic whose distribution for unauthorized uses is a specific federal crime in the United States, and the other holds no approval anywhere and reaches consumers under a research use only disclaimer that guarantees nothing about identity, purity, sterility, or manufacturing control.
Neither HGH Fragment 176-191 nor AOD-9604 holds a therapeutic approval in any country, and in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted unanimously against adding the analogue to the section 503A bulk drug substances list.
Two different safety questions get collapsed into one. The trial-grade question, how the molecule behaved in monitored adults given verified material for months, has a narrow reassuring answer, while the market question, what is actually inside a gray-market vial, has a much worse one.
The controlled-condition tolerability record covers months of pharmaceutical-grade material in screened adults, while independent testing of gray-market peptide vials has repeatedly found wrong identity, mis-stated content, endotoxin, and in some cases no active peptide at all.
The distance between the literature and the sales copy follows a predictable pattern. The most common claim, growth hormone's fat loss without growth hormone's side effects, is half accountable to evidence: the missing side effects match the mechanism and the trial data, and the fat loss is exactly the half that failed in the confirmatory human trial. Reviewers of this literature separate the halves by asking whether a study was in humans, whether it was randomized and placebo-controlled, and whether it tested the exact molecule being sold.
| Market claim | Published record |
|---|---|
| Fat loss without growth hormone side effects | Side-effect absence supported, fat loss failed the confirmatory trial |
| Targeted or spot fat reduction | No support in any human study, contrary to fat mobilization physiology |
| Sleep, recovery, anti-aging, skin, cartilage | Borrowed from somatotropin's reputation or unrelated exploratory work |
| Rodent findings stated in human terms | Genetically obese mouse data presented as an implied clinical result |
| AOD-9604 and 176-191 used interchangeably | Chemically distinct, only the analogue went through human trials |
Applied to the fat-loss claim this compound is marketed on, all three filters fail, since the confirmatory human trial found no effect, the trial tested AOD-9604 rather than the native 176-191 sequence, and no placebo-controlled human efficacy trial of the injected native fragment exists.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
